Browse the evidence

New dietary interventions are poised to overtake traditional strategies as the ideal approach to achieving sustained weight loss for obesity-associated hypertension patients.

Practitioners should consider implementing new dietary interventions for better weight loss outcomes in patients.

Eine Gewichtsabnahme kann die urogynäkologischen Symptome verbessern, bei 5–10% Gewichtsreduktion wird ein Rückgang der Inkontinenzepisoden bis zu 60% beschrieben.

Gewichtsreduktion sollte als Therapieoption zur Verbesserung urogynäkologischer Symptome in Betracht gezogen werden.

Bariatric surgery is the most effective treatment for obesity, yielding sustainable weight loss of about 20-30%.

Bariatric surgery should be considered for patients with obesity seeking significant weight loss.

GLP-1 receptor agonist semaglutide 2.4 mg and dual GLP-1 and GIP agonist tirzepatide have raised the bar for weight loss efficacy in obesity pharmacotherapies.

Clinicians should consider GLP-1 and GIP agonists as effective options for obesity treatment.

Combinations of GLP-1 RA, GIP, and glucagon RA (retatrutide) have shown weight loss efficacy approaching that of bariatric surgery.

Combination therapies may offer significant weight loss benefits similar to surgical options.

Pharmacotherapy is highly effective in reducing body weight and improving metabolic parameters.

Pharmacotherapy should be considered as a key component in obesity treatment plans.

Psychological support, including cognitive-behavioral therapy, increases patient adherence and improves long-term outcomes.

Incorporating psychological support can enhance treatment adherence and effectiveness.

Second-generation drugs for obesity treatment can achieve weight loss of 15-25%, comparable to bariatric surgery.

Healthcare professionals can consider second-generation drugs as effective options for weight management in obese patients.

GLP-1 receptor agonists can achieve weight loss of 15-17% with a good safety profile.

GLP-1 receptor agonists are a viable treatment option for weight loss in obese patients.

Tirzepatide can achieve weight loss of up to 22.5% at the highest doses.

Tirzepatide represents a potent option for significant weight loss in obese patients.

Obesity has been associated with an increased risk of all-cause and cardiovascular mortality.

Awareness of the mortality risks associated with obesity is essential for patient management.

Once-weekly GLP-1RA therapy can produce substantial weight loss over prolonged treatment (up to 23% at 72 weeks), alongside improvements in metabolic outcomes and reduced cardiometabolic risk.

GLP-1RA therapies can be effective for significant weight loss and improving metabolic health in obese patients.

Inkretin-basierte Medikamente (GLP-1- und GIP/GLP-1-Rezeptoragonisten) und SGLT-2-Inhibitoren (SGLT2i) ermöglichen eine bislang nicht erreichte Gewichtsreduktion und reduzieren nachweislich kardiovaskuläre Ereignisse (MACE).

Practitioners should consider these medications as effective options for weight management and cardiovascular risk reduction.

Die Kombination von GLP-1-Rezeptoragonisten und SGLT2i zeigt additive Vorteile und wird leitliniengerecht bei Typ-2-Diabetes mit hohem Risiko empfohlen.

Healthcare providers should consider this combination therapy for high-risk type 2 diabetes patients.

Cognitive–behavioral methods focusing on emotional eating lead to greater improvements in emotional eating and related weight and waist circumference reductions compared to education-based approaches.

Practitioners should consider implementing cognitive-behavioral strategies that focus on emotional eating in obesity treatment programs.

Lessened emotional eating is significantly associated with concurrent reductions in weight and waist circumference.

Reducing emotional eating can be an effective strategy for achieving weight loss and waist circumference reduction.

Median time to maintenance was significantly shorter for Tirzepatide (32 days) than Semaglutide (143 days).

Practitioners may prefer Tirzepatide for quicker dose optimization.

Obesity medications (OMs) produce meaningful weight loss (∼5%-24%) and improve cardiometabolic health.

Practitioners can expect significant weight loss and health benefits from OMs.

Advanced pharmacotherapy with GLP-1 receptor agonists can achieve 15%–20% weight loss.

Clinicians can consider GLP-1 receptor agonists as an effective pharmacotherapy option for weight loss.

Bariatric and metabolic surgery is more effective than medicinal treatment for reversing NASH and improving liver fibrosis.

Practitioners should consider bariatric surgery as a treatment option for patients with NASH who are also obese and have type 2 diabetes.

Weight loss of at least 10% is required to achieve meaningful clinical remission rates in NASH.

Weight management strategies should aim for at least a 10% reduction in body weight for patients with NASH.

Recent antiobesity drugs have shown weight loss effects of 12%–17% and can resolve NASH in some patients.

Consider the use of antiobesity medications as part of a comprehensive treatment plan for NASH.

At 15 months, total body weight loss (TBWL) was greater in mild versus severe IMS groups (14.8% vs. 11.0%, p = 0.015).

Clinicians should consider IMS severity when predicting weight loss outcomes with tirzepatide.

The proportion achieving ≥ 20% TBWL was nearly two-fold higher in mild versus severe IMS (27% vs. 14%, p = 0.03).

Higher IMS severity is associated with lower chances of achieving significant weight loss with tirzepatide.